Evidence map›Paper›PMID 23763575›Full record

ArticleBiochemistry2013

A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid.

Sook-Kyung Lee, Nancy Cheng, Emily Hull-Ryde, Marc Potempa, Celia A Schiffer, William Janzen, Ronald Swanstrom

Open access · greenAbstract readValidation Study
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sook-Kyung LeeDepartment of Biochemistry and Biophysics and UNC Center for AIDS Research, ‡Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, §Department of Microbiology and Immunology, and ∥Cancer Genetics Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Nancy Cheng
Emily Hull-Ryde
Marc Potempa
Celia A Schiffer
William Janzen
Ronald Swanstrom
University of Massachusetts Chan Medical School · USInstitute of Molecular Biology and Biophysics · RUUniversity of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Targeting ensembles of Drug Resistant HIV ProteasesP01GM066524 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RANA, TARIQ M · 2002 to 2011
$16.3M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
Targeting Drug Resistance in HIV-1 ProteaseR01GM064347 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHIFFER, CELIA A. · 2001 to 2013
$4.5M
High Throughput Screen For HIV-1 MA/CA Processing Site InhibitorsR21NS073052 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JANZEN, WILLIAM PERRY, SWANSTROM, RONALD I · 2011 to 2011
$148k
NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA16086NIAID NIH HHS P30 AI050410NIAID NIH HHS P30-AI50410NIAID NIH HHS T32 AI007001NIGMS NIH HHS P01 GM066524NIGMS NIH HHS P01-GM066524NIGMS NIH HHS R01 GM064347NIGMS NIH HHS R01GM65347NINDS NIH HHS R21 NS073052
6 · The paper itself

Abstract

The matrix/capsid processing site in the HIV-1 Gag precursor is likely the most sensitive target to inhibit HIV-1 replication. We have previously shown that modest incomplete processing at the site leads to a complete loss of virion infectivity. In the study presented here, a sensitive assay based on fluorescence polarization that can monitor cleavage at the MA/CA site in the context of the folded protein substrate is described. The substrate, an MA/CA fusion protein, was labeled with the fluorescein-based FlAsH (fluorescein arsenical hairpin) reagent that binds to a tetracysteine motif (CCGPCC) that was introduced within the N-terminal domain of CA. By limiting the size of CA and increasing the size of MA (with an N-terminal GST fusion), we were able to measure significant differences in polarization values as a function of HIV-1 protease cleavage. The sensitivity of the assay was tested in the presence of increasing amounts of an HIV-1 protease inhibitor, which resulted in a gradual decrease in the fluorescence polarization values demonstrating that the assay is sensitive in discerning changes in protease processing. The high-throughput screening assay validation in 384-well plates showed that the assay is reproducible and robust with an average Z' value of 0.79 and average coefficient of variation values of <3%. The robustness and reproducibility of the assay were further validated using the LOPAC(1280) compound library, demonstrating that the assay provides a sensitive high-throughput screening platform that can be used with large compound libraries for identifying novel maturation inhibitors targeting the MA/CA site of the HIV-1 Gag polyprotein.

Indexed as

CapsidCell LineFluoresceinHIV-1HIV ProteaseHumansSubstrate SpecificityVirus AssemblyVirus ReplicationFluoresceinHIV Protease

Identifiers

PMID23763575
PMCPMC3855639
OpenAlexW2075199373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.